United Kingdom

Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

Clinical Examination of Cavovarus Feet

A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

Real World Data Collection in Subjects Treated With the FARAPULSE Pulsed Field Ablation System

WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma

A Trial of Lu AG13909 in Adult Participants With Cushing's Disease

A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)

A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD

Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)